NVIV
Price
$0.80
Change
+$0.01 (+1.27%)
Updated
Dec 7, 6:59 PM EST
83 days until earnings call
RANI
Price
$2.61
Change
+$0.09 (+3.57%)
Updated
Dec 7, 6:59 PM EST
110 days until earnings call
Ad is loading...

Analysis and predictions NVIV vs RANI

Header iconNVIV vs RANI Comparison
Open Charts NVIV vs RANIBanner chart's image
InVivo Therapeutics Holdings
Price$0.80
Change+$0.01 (+1.27%)
Volume$21.41K
CapitalizationN/A
Rani Therapeutics Holdings
Price$2.61
Change+$0.09 (+3.57%)
Volume$41.18K
CapitalizationN/A
View a ticker or compare two or three
NVIV vs RANI Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
NVIV vs. RANI commentary
Dec 08, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVIV is a Sell and RANI is a StrongBuy.

COMPARISON
Comparison
Dec 08, 2023
Stock price -- (NVIV: $0.80 vs. RANI: $2.59)
Brand notoriety: NVIV and RANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVIV: 99% vs. RANI: 164%
Market capitalization -- NVIV: $2.07M vs. RANI: $51.24M
NVIV [@Biotechnology] is valued at $2.07M. RANI’s [@Biotechnology] market capitalization is $51.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVIV’s FA Score shows that 1 FA rating(s) are green whileRANI’s FA Score has 0 green FA rating(s).

  • NVIV’s FA Score: 1 green, 4 red.
  • RANI’s FA Score: 0 green, 5 red.
According to our system of comparison, NVIV is a better buy in the long-term than RANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVIV’s TA Score shows that 4 TA indicator(s) are bullish while RANI’s TA Score has 5 bullish TA indicator(s).

  • NVIV’s TA Score: 4 bullish, 4 bearish.
  • RANI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RANI is a better buy in the short-term than NVIV.

Price Growth

NVIV (@Biotechnology) experienced а +21.19% price change this week, while RANI (@Biotechnology) price change was +32.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.23%. For the same industry, the average monthly price growth was +6.91%, and the average quarterly price growth was +25.39%.

Reported Earning Dates

NVIV is expected to report earnings on Feb 28, 2024.

RANI is expected to report earnings on Mar 26, 2024.

Industries' Descriptions

@Biotechnology (+6.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NVIV with price predictions.
OPEN
A.I.dvisor published
a Summary for RANI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RANI($51.2M) has a higher market cap than NVIV($2.07M). RANI YTD gains are higher at: -55.763 vs. NVIV (-65.957). NVIV has higher annual earnings (EBITDA): -9.44M vs. RANI (-65.93M). RANI has more cash in the bank: 60.5M vs. NVIV (8.58M). NVIV has less debt than RANI: NVIV (0) vs RANI (30.3M). NVIV (0) and RANI (0) have equivalent revenues.
NVIVRANINVIV / RANI
Capitalization2.07M51.2M4%
EBITDA-9.44M-65.93M14%
Gain YTD-65.957-55.763118%
P/E Ratio0.61N/A-
Revenue00-
Total Cash8.58M60.5M14%
Total Debt030.3M-
FUNDAMENTALS RATINGS
NVIV: Fundamental Ratings
NVIV
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
95
SEASONALITY SCORE
1..100
45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NVIVRANI
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 18 days ago
78%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TELL0.650.08
+14.68%
Tellurian
MSM98.210.79
+0.81%
MSC Industrial Direct Co
ACN335.18-0.23
-0.07%
Accenture PLC
HSAI9.45-0.09
-0.94%
Hesai Group American Depositary Share each ADS represents one
ESLA1.20-0.11
-8.40%
Estrella Immunopharma

NVIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVIV has been loosely correlated with ATXI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NVIV jumps, then ATXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVIV
1D Price
Change %
NVIV100%
+5.26%
ATXI - NVIV
37%
Loosely correlated
-8.45%
SAGE - NVIV
29%
Poorly correlated
+0.19%
RANI - NVIV
29%
Poorly correlated
+0.77%
SNTI - NVIV
28%
Poorly correlated
+7.06%
MDGL - NVIV
27%
Poorly correlated
-0.32%
More

RANI and

Correlation & Price change

A.I.dvisor tells us that RANI and UBX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RANI and UBX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RANI
1D Price
Change %
RANI100%
+0.77%
UBX - RANI
31%
Poorly correlated
+2.15%
FATE - RANI
28%
Poorly correlated
-2.08%
NVIV - RANI
28%
Poorly correlated
+5.26%
MORF - RANI
28%
Poorly correlated
+3.06%
CAPR - RANI
27%
Poorly correlated
+1.48%
More